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Abstract 44 
Introduction: Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety 45 
of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line therapy for 46 
advanced nonsquamous NSCLC. At the primary analysis (median follow-up, 10.6 months), 47 
pembrolizumab significantly improved objective response rate (ORR) and progression-free 48 
survival (PFS); hazard ratio (HR) for overall survival (OS) was 0.90 (95% CI, 0.42‒1.91). 49 
Herein, we present an updated analysis. 50 
Methods: 123 patients with previously untreated stage IIIB/IV nonsquamous NSCLC without 51 
EGFR/ALK aberrations were randomized 1:1 to 4 cycles of PC with/without pembrolizumab 200 52 
mg Q3W. Pembrolizumab treatment continued for 2 years; maintenance pemetrexed was 53 
permitted in both groups. Eligible patients in the PC alone group with radiologic progression 54 
could cross over to pembrolizumab monotherapy. P values are nominal (one-sided P<0.025). 55 
Results: As of December 1, 2017, median follow-up was 23.9 mo. ORR was 56.7% with 56 
pembrolizumab plus PC versus 30.2% with PC alone (estimated difference, 26.4%; 95% CI, 57 
8.9%‒42.4%; P=0.0016). PFS was significantly improved with pembrolizumab plus PC versus 58 
PC alone (HR, 0.53; 95% CI, 0.33‒0.86; P=0.0049). 41 patients in the PC alone group received 59 
subsequent anti-PD-1/anti-PD-L1 therapy. The HR for OS was 0.56 (95% CI, 0.32‒0.95; 60 
P=0.0151). 41% of patients in the pembrolizumab plus PC group and 27% in the PC alone group 61 
had grade 3‒5 treatment-related adverse events. 62 
Conclusions: Significant improvements in PFS and ORR with pembrolizumab plus PC versus 63 
PC alone observed in the primary analysis were maintained and the HR for OS with 24-month 64 
median follow-up was 0.56, favoring pembrolizumab plus PC. 65 
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Introduction 70 
Platinum-doublet chemotherapy has been the standard of care for first-line treatment of patients 71 
with advanced non‒small-cell lung cancer (NSCLC) without targetable genetic aberrations.1 72 
Monotherapy with pembrolizumab, an anti‒programmed death (PD)-1 monoclonal antibody, has 73 
demonstrated a benefit in both progression-free survival (PFS) and overall survival (OS) 74 
compared with platinum-based chemotherapy as first-line therapy for patients with advanced 75 
NSCLC with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.2 An 76 
OS benefit was also demonstrated with pembrolizumab compared with docetaxel in previously 77 
treated patients with advanced NSCLC with a PD-L1 TPS ≥1%.3 Because chemotherapy 78 
mediates immunologic effects,4 combining chemotherapy with anti–PD-1 immunotherapy may 79 
have a synergistic antitumor effect. 80 
We previously published results from the primary analysis of cohort G of the multicohort phase 81 
1/2 KEYNOTE-021 study (ClinicalTrials.gov, NCT02039674), an open-label, randomized phase 82 
2 trial that evaluated pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone in 83 
patients with previously untreated advanced nonsquamous NSCLC.5 With a minimum 6-month 84 
follow-up (median 10.6 months), patients in the pembrolizumab plus PC group had significant 85 
improvements in both the objective response rate (ORR, 55% versus 29%; P=0.0016) and PFS 86 
(hazard ratio [HR], 0.53; 95% CI, 0.31‒0.91; P=0.010), with a manageable safety profile. The 87 
HR for OS was 0.90 (95% CI, 0.42‒1.91; nominal P=0.39), although only 27 of 123 patients 88 
(22%) had died at the time of the initial analysis. Based on these results, pembrolizumab plus PC 89 
has received accelerated approval from the US Food and Drug Administration (FDA) for first-90 
line treatment of metastatic nonsquamous NSCLC.6 Herein, we report updated efficacy and 91 
safety with a median follow up of approximately 24 months.  92 
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Methods 93 
Full eligibility criteria and other aspects of the study design and protocol (MK-3475-021-03) 94 
have been described previously.5 In brief, to be eligible for cohort G of KEYNOTE-021, patients 95 
were required to have previously untreated stage IIIB/IV nonsquamous NSCLC without 96 
activating EGFR mutations or ALK translocations, Eastern Cooperative Oncology Group 97 
performance status 0 or 1, no untreated brain metastases, and no interstitial lung disease or 98 
pneumonitis requiring systemic steroids. All patients were required to provide a tumor sample 99 
for assessment of tumor PD-L1 expression. Patients were stratified by PD-L1 TPS (<1% or ≥1%) 100 
and randomized to receive PC (pemetrexed 500 mg/m2 plus carboplatin area under the 101 
concentration time curve [AUC] 5 mg/mL/min every 3 weeks [Q3W] for 4 cycles), alone or with 102 
pembrolizumab 200 mg Q3W for 2 years. Pemetrexed 500 mg/m2 Q3W was permitted as 103 
maintenance therapy and continued in the absence of disease progression or unacceptable 104 
toxicity. Patients in the PC alone group could cross over to receive pembrolizumab monotherapy 105 
at the time of disease progression if they met eligibility criteria.  106 
The primary endpoint was ORR and PFS was the key secondary endpoint; both were evaluated 107 
by blinded independent central review. OS was an additional secondary endpoint. Planned 108 
enrollment (in the primary analysis) was 108 patients. The primary analysis (one-sided 109 
alpha=0.025) was controlled by a fixed-sequence, closed-testing procedure stepping down from 110 
ORR to PFS. Because no alpha was assigned for this analysis, all reported P values are 111 
descriptive (one-sided P<0.025). 112 
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Results 113 
Overall, 123 patients were randomized (pembrolizumab plus PC, n=60; PC alone, n=63). 114 
Baseline demographic and clinical characteristics have been previously reported.5 One patient in 115 
each treatment group did not initiate treatment. At the current data cutoff (December 1, 2017), 116 
median follow up across both treatment groups was 23.9 months (range, 0.8–35.1 months). 117 
Median duration of randomized treatment was 10.1 months (range, 0–29.0 months) in patients 118 
treated with pembrolizumab plus PC and 4.9 months (range, 0–31.0 months) for patients treated 119 
with PC alone. Of the 59 patients treated with pembrolizumab plus PC, 5 (8.5%) were continuing 120 
treatment as of the data cut-off, and 11 (18.6%) had completed treatment; 43 (72.9%) 121 
discontinued treatment (n=26 for progression). Of the 62 patients treated with PC, 6 patients 122 
(9.7%) were continuing treatment, and 2 (3.2%) had completed treatment; 54 (87.1%) had 123 
discontinued treatment (38  due to disease progression). Among the 56 patients in the PC alone 124 
group who had discontinued or completed treatment, 26 patients (46.4%) crossed over to 125 
pembrolizumab on study and 15 additional patients (26.8%) received anti‒PD-1/PD-L1 therapy 126 
outside of crossover. Patients in the pembrolizumab plus PC group received a median of 14 127 
(range, 1 to 41) cycles of pembrolizumab. Fifty-two patients (88.1%) in the pembrolizumab plus 128 
PC group and 44 (71.0%) in the PC alone group received 4 cycles of carboplatin. All patients in 129 
both treatment groups received ≥1 cycle of pemetrexed; 50 patients (84.8%) in the 130 
pembrolizumab plus PC group and 42 (67.7%) in the PC alone group received more than the 131 
initial 4 planned cycles of pemetrexed induction (ie, received maintenance pemetrexed). The 132 
median number of cycles of pemetrexed was 14 in the pembrolizumab plus PC group and 42 in 133 
the PC alone group. 134 
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Compared with the prespecified primary analysis,5 2 additional confirmed responses were 135 
identified in the pembrolizumab plus PC group (n=1) or PC alone group (n=1). The ORR was 136 
56.7% with pembrolizumab plus PC and 30.2% with PC alone, with a between-group difference 137 
in ORR of 26.4% (95% CI, 8.9%–42.4%; nominal P=0.0016). Among the responses observed, 1 138 
patient in each group experienced a complete response that had evolved from a partial response 139 
at the previous analysis. Median response duration had not been reached (NR) in patients treated 140 
with pembrolizumab plus PC (range, 1.4 [ongoing] to 29.3 months [ongoing]) or PC alone 141 
(range, 2.8 [ongoing] to 30.1 months [ongoing]). At the time of data cutoff, 47% of responders in 142 
the pembrolizumab plus PC group and 32% in the PC alone group had ongoing responses.  143 
As of this updated analysis, disease progression or death had occurred in 28 of 60 patients (47%) 144 
in the pembrolizumab plus PC group and 43 of 63 patients (68%) in the PC alone group. The HR 145 
for PFS was 0.53 (95% CI, 0.33–0.86; nominal P=0.0049), with a median PFS of 24.0 months in 146 
patients in the pembrolizumab plus PC group and 9.3 months for patients in the PC alone group 147 
(Figure 1A).  148 
At the time of analysis, 22 of 60 patients (37%) in the pembrolizumab plus PC group and 35 of 149 
63 patients (56%) in the PC alone group had died. Of the 35 deceased patients in the PC alone 150 
group, 26 (74%) had received second-line immunotherapy. This represents an additional 30 151 
deaths since the initial report (9 in the pembrolizumab plus PC group; 21 in the PC alone 152 
group).5 The HR for OS was 0.56 (95% CI, 0.32–0.95; nominal P=0.0151). Median OS was NR 153 
in the pembrolizumab plus PC group (95% CI, 24.5 to NR months) and 21.1 months (95% CI, 154 
14.9 to NR months) in the PC alone group (Figure 1B). 155 
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There were no new safety trends observed since the initial report. As of the current analysis, 55 156 
of 59 patients (93.2%) in the pembrolizumab plus PC group and 57 of 62 patients (91.9%) in the 157 
PC alone group experienced treatment-related adverse events (AEs; Table). Ten patients 158 
(16.9%) in the pembrolizumab plus PC group and 8 (12.9%) in the PC alone group experienced 159 
treatment-related AEs that led to discontinuation of any component of study medication. Grade 160 
3–5 treatment-related AEs occurred in 24 patients (40.7%) and 17 patients (27.4%), respectively. 161 
Treatment-related fatal AEs occurred in 1 patient in the pembrolizumab plus PC group (1.7%; 162 
sepsis) and 2 patients in the PC group (3.2%; pancytopenia and sepsis), with no additional deaths 163 
occurring since the initial analysis. AEs with a presumed immunological mechanism of action 164 
(regardless of attribution to study treatment or immune relatedness by the investigator) occurred 165 
in 17 patients (28.8%) in the pembrolizumab plus PC group and 7 patients (11.3%) in the PC 166 
alone group.  167 
Discussion 168 
In this updated analysis, the HR for OS for pembrolizumab plus PC versus PC alone after a 169 
median 23.9-month follow-up was 0.56 (95% CI, 0.32–0.95; nominal P=0.0151), compared with 170 
an HR of 0.90 in the primary analysis (median 10.6-month follow-up).5 The HR for OS favoring 171 
the pembrolizumab plus PC group occurred despite a high effective crossover rate to anti‒PD-172 
1/PD-L1 therapy in the PC alone group and despite the OS in the PC alone group exceeding that 173 
for historical controls.7 Statistically significant and clinically meaningful improvements in ORR 174 
and PFS observed in prior analyses of KEYNOTE-021G were maintained in this updated 175 
analysis. At the time of the current data cutoff, median PFS in the pembrolizumab plus PC group 176 
was 24.0 months. As with OS, median PFS in the PC alone arm (9.3 months) was also longer 177 
than previously reported with pemetrexed-platinum in patients with NSCLC.2,7 The relatively 178 
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long OS and PFS in the PC alone arm may have been due, at least in part, to the eligibility 179 
criteria excluding patients with poor prognosis (eg, untreated brain metastases).  180 
The findings from this phase 2 study have subsequently been confirmed by results from the 181 
phase 3 KEYNOTE-189 study, where pembrolizumab plus pemetrexed-platinum  reduced the 182 
risk of death by more than half compared with placebo plus pemetrexed-platinum (OS HR, 0.49 183 
[95% CI, 0.38–0.64]; P<0.001) in previously untreated metastatic nonsquamous NSCLC without 184 
sensitizing EGFR mutations or ALK translocations.8 Notably, the OS benefit observed with the 185 
combination of pembrolizumab plus pemetrexed and platinum in KEYNOTE-189 occurred 186 
regardless of tumor PD-L1 expression, with similar HRs across all PD-L1 TPS subgroups (TPS 187 
≥50%, 0.42 [95% CI, 0.26–0.68]; TPS 1–49%, 0.55 [95% CI, 0.34–0.90]; TPS <1%, 0.59 [95% 188 
CI, 0.38-0.92]). Likewise, KEYNOTE-189 confirmed superior PFS with pembrolizumab plus 189 
pemetrexed-platinum over placebo plus pemetrexed-platinum with a similar HR for PFS (0.52 190 
[95% CI, 0.43–0.64]; P<0.001) to that shown in this long-term analysis from KEYNOTE-021 191 
cohort G.8  192 
In addition to the noteworthy efficacy findings with long-term follow up in KEYNOTE-021 193 
cohort G, the combination of pembrolizumab plus PC continued to show a manageable safety 194 
profile. In comparison with pembrolizumab monotherapy in KEYNOTE-024, a greater 195 
percentage of patients treated with pembrolizumab plus PC in this long-term analysis of 196 
KEYNOTE-021 cohort G experienced treatment-related AEs leading to discontinuation (7% vs 197 
17%, respectively) and grade 3-5 treatment-related AEs (27% vs 41%, respectively).2 However, 198 
additional toxicity with a combination treatment regimen containing platinum chemotherapy is 199 
not unexpected. Importantly, in the larger, double-blind, placebo-controlled, phase 3 study, 200 
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KEYNOTE-189, there was no evidence that AEs commonly associated with pemetrexed-201 
platinum were exacerbated with the addition of pembrolizumab; the exception may be renal 202 
toxicity, which was overall manageable.8 Moreover, the increased toxicity with pembrolizumab 203 
plus PC compared with pembrolizumab alone may be offset by improved efficacy outcomes. 204 
Although cross-trial comparisons should be made with caution, it is notable that the OS HR of 205 
0.42 for patients with PD-L1 TPS ≥50% in KEYNOTE-1898 compares favorably with the OS 206 
HR of 0.58 (95% CI, 0.41–0.83) for the nonsquamous subgroup of KEYNOTE-024.9 Notably, 207 
outcomes for patients with TPS ≥50% and any histology treated with pembrolizumab versus 208 
platinum-based chemotherapy in the phase 3 KEYNOTE-042 study were similar (OS HR, 0.69 209 
[95% CI, 0.56–0.85]).10 Pembrolizumab plus PC, which has been granted accelerated FDA 210 
approval, represents an effective and tolerable treatment option for use as initial therapy for 211 
eligible patients with advanced nonsquamous NSCLC.  212 
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Table. Incidence of Adverse Events 283 
 
Pembrolizumab plus PC 
N=59  
PC Alone 
N=62 
Treatment-related AEs, n (%)    
 Any grade 55 (93)  57 (92) 
 Grades 3–5 24 (41)  17 (27) 
 Leading to discontinuationa 10 (17)  8 (13) 
 Leading to death 1 (2)  2 (3) 
Treatment-related AEs occurring in  
≥15% of patients, n (%) Any Grade Grades 3/4  Any Grade Grades 3/4 
 Fatigue 40 (68) 2 (3)  27 (44) 0 (0) 
 Nausea 35 (59) 1 (2)  30 (48) 0 (0) 
 Anemia 20 (34) 7 (12)  33 (53) 8 (13) 
 Vomiting 18 (31) 1 (2)  11 (18) 0 (0) 
 Rash 17 (29) 1 (2)  9 (15) 0 (0) 
 Diarrhea 14 (24) 0 (0)  9 (15) 1 (2) 
 Decreased appetite 13 (22) 0 (0)  12 (19) 0 (0) 
 Aspartate aminotransferase 
increased 11 (19) 1 (2)  8 (13) 1 (2) 
 Constipation 11 (19) 0 (0)  6 (10) 0 (0) 
 Dysgeusia 11 (19) 0 (0)  7 (11) 0 (0) 
 Alanine aminotransferase increased 10 (17) 1 (2)  8 (13) 1 (2) 
 Blood creatinine increased 10 (17) 0 (0)  4 (7) 0 (0) 
 Neutrophil count decreased 10 (17) 4 (7)  8 (13) 2 (3) 
 Lacrimation increased 9 (15) 0 (0)  8 (13) 0 (0) 
Pruritus 9 (15)   3 (5)  
Immune-mediated AEs,b n (%) Any Grade Grades 3/4  Any Grade Grades 3/4 
 Hypothyroidism 9 (15) 0 (0)  2 (3) 0 (0) 
 Hyperthyroidism 6 (10) 0 (0)  1 (2) 0 (0) 
 Pneumonitis 4 (7) 1 (2)  0 (0) 0 (0) 
 Infusion reactions 1 (2) 1 (2)  3 (5) 0 (0) 
 Severe skin toxicity 1 (2) 1 (2)  1 (2) 1 (2) 
 Colitis 1 (2) 0 (0)  0 (0) 0 (0) 
AE, adverse event; PC, pemetrexed-carboplatin. 284 
aAny component of study medication. 285 
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bAdverse events with a possible immune etiology regardless of attribution to study treatment or 286 
immune-relatedness by the investigator. 287 
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Figure Legend 288 
Figure 1. Kaplan-Meier analysis of A) progression-free survival (RECIST v1.1 by blinded, 289 
independent central review) and B) overall survival. aP value is descriptive (one-290 
sided P<0.025). RECIST=Response Evaluation Criteria in Solid Tumors.  291 
 292 
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Figure 1. 293 
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